



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Dehydrojuncusol

Cat. No.:	HY-N8188
CAS No.:	117824-04-1
Molecular Formula:	C ₁₈ H ₁₆ O ₂
Molecular Weight:	264.32
Target:	HCV; HCV Protease
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC ₅₀ =1.35 μM) ^[1] .
In Vitro	<p>Dehydrojuncusol (Huh-7 cells were infected with HCV in cell culture; 0-9.4 μM; 48 hours) inhibits HCV infection in a dose-dependent manner. Dehydrojuncusol inhibits HCV infection in Primary human hepatocytes (PHH)^[1].</p> <p>The EC₅₀ of dehydrojuncusol is 1.35 μM when added continuously, 8.21 μM when added during inoculation, and 1.53 μM when added postinoculation, confirming the major effect of the molecule at the postinoculation step. The toxicity of the compound on Huh-7 cells is also tested in parallel at different time points (24h, 48h, and 72h). The results shows that the CC₅₀ of Dehydrojuncusol is approximately 75.6 μM, which is much higher than the active dose, yielding a selective index of 56^[1].</p> <p>Dehydrojuncusol is able to inhibit RNA replication of two frequent daclatasvir-resistant mutants (L31M or Y93H in NS5A). Dehydrojuncusol inhibits HCV RNA replication^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Sahuc ME, et al. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from *Juncus maritimus*, Is a New Inhibitor of Hepatitis C Virus RNA Replication. *J Virol*. 2019;93(10):e02009-18. Published 2019 May 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA